1. Ma, LY, Chen, WW, Gao, RL, et al. China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol. 2020;17:1‐8.
Google Scholar | Medline2. Vítek, L . The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.
Google Scholar | Crossref | Medline | ISI3. Green, RM, Flamm, S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123:1367‐84.
Google Scholar | Crossref | Medline | ISI4. Mayer, M . Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 2000;46:1723‐7.
Google Scholar | Crossref | Medline | ISI5. Neuzil, J, Stocker, R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Letters. 1993;331:281‐4.
Google Scholar | Crossref | Medline | ISI6. Wu, TW, Fung, KP, Yang, CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci. 1994;54:P477‐81.
Google Scholar | Crossref | Medline | ISI7. Novotný, L, Vítek, L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med. 2003;228:568‐71.
Google Scholar | SAGE Journals | ISI8. Vítek, L, Jirsa, M, Brodanová, M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis. 2002;160:449‐56.
Google Scholar | Crossref | Medline | ISI9. Song, YS, Koo, BK, Cho, NH, Moon, MK. Effect of low serum total bilirubin levels (≤0.32 mg/dl) on risk of coronary artery disease in patients with metabolic syndrome. Am J Cardiol. 2014;114:1695‐700.
Google Scholar | Crossref | Medline | ISI10. Chen, YH, Hung, SC, Tarng, DC. Serum bilirubin links UGT1A1*28 polymorphism and predicts long-term cardiovascular events and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:567‐74.
Google Scholar | Crossref | Medline | ISI11. Djoussé, L, Levy, D, Cupples, LA, Evans, JC, D’Agostino, RB, Ellison, RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol. 2001;87:1196‐200.
Google Scholar | Crossref | Medline | ISI12. Hopkins, PN, Wu, LL, Hunt, SC, James, BC, Vincent, GM, Williams, RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16:250‐5.
Google Scholar | Crossref | Medline | ISI13. Horsfall, LJ, Nazareth, I, Petersen, I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012;126:2556‐64.
Google Scholar | Crossref | Medline | ISI14. Hunt, SC, Kronenberg, F, Eckfeldt, JH, Hopkins, PN, Myers, RH, Heiss, G. Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study. Atherosclerosis. 2001;154:747‐54.
Google Scholar | Crossref | Medline | ISI15. Kimm, H, Yun, JE, Jo, J, Jee, SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke. 2009;40:3422‐7.
Google Scholar | Crossref | Medline | ISI16. Schwertner, HA, Jackson, WG, Tolan, G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994;40:18‐23.
Google Scholar | Crossref | Medline | ISI17. Schooling, CM, Kelvin, EA, Jones, HE. Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III. Ann Epidemiol. 2012;22:789‐98.
Google Scholar | Crossref | Medline18. Temme, EH, Zhang, J, Schouten, EG, Kesteloot, H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control. 2001;12:887‐94.
Google Scholar | Crossref | Medline | ISI19. Breimer, LH, Wannamethee, G, Ebrahim, S, Shaper, AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem. 1995;41:1504‐8.
Google Scholar | Crossref | Medline | ISI20. Troughton, JA, Woodside, JV, Young, IS, et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil. 2007;14:79‐84.
Google Scholar | SAGE Journals21. Kunutsor, SK, Bakker, SJ, Gansevoort, RT, Chowdhury, R, Dullaart, RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35:716‐24.
Google Scholar | Crossref | Medline | ISI22. Page, MJ, McKenzie, JE, Bossuyt, PM, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103‐112.
Google Scholar | Crossref | Medline23. Brown, D . A review of the pubmed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020;21:496‐498.
Google Scholar | SAGE Journals | ISI24. Stang, A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603‐605.
Google Scholar | Crossref | Medline | ISI25. Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327 557‐560.
Google Scholar | Crossref | Medline26. Ajja, R, Lee, DC, Sui, X, Church, TS, Steven, NB. Usefulness of serum bilirubin and cardiorespiratory fitness as predictors of mortality in men. Am J Cardiol. 2011;108:1438‐42.
Google Scholar | Crossref | Medline | ISI27. Lai, X, Fang, Q, Yang, L, et al. Direct, indirect and total bilirubin and risk of incident coronary heart disease in the Dongfeng-Tongji cohort. Ann Med. 2018;50:16‐25.
Google Scholar | Crossref | Medline28. Suh, S, Cho, YR, Park, MK, Kim, DK, Cho, NH, Lee, MK. Relationship between serum bilirubin levels and cardiovascular disease. PLoS One. 2018;13:e0193041.
Google Scholar | Crossref | Medline29. Ekblom, K, Marklund, SL, Jansson, JH, et al. Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting. Circ Cardiovasc Genet. 2010;3:340‐7.
Google Scholar | Crossref | Medline | ISI30. Ekblom, K, Marklund, SL, Johansson, L, et al. Bilirubin and UGT1A1*28 are not associated with lower risk for ischemic stroke in a prospective nested case-referent setting. Cerebrovasc Dis. 2010;30:590‐6.
Google Scholar | Crossref | Medline | ISI31. Oda, E, Kawai, R. A possible cross-sectional association of serum total bilirubin with coronary heart disease and stroke in a Japanese health screening population. Heart Ves. 2012;27:29‐36.
Google Scholar | Crossref | Medline32. Tanaka, M, Fukui, M, Tomiyasu, K, et al. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis. 2009;206:287‐91.
Google Scholar | Crossref | Medline | ISI33. Vera, T, Granger, JP, Stec, DE. Inhibition of bilirubin metabolism induces moderate hyperbilirubinemia and attenuates ANG II-dependent hypertension in mice. Am J Physiol Regul Integr Comp Physiol. 2009;297:R738‐43.
Google Scholar | Crossref | Medline34. Endler, G, Hamwi, A, Sunder-Plassmann, R, et al. Is low serum bilirubin an independent risk factor for coronary artery disease in men but not in women? Clin Chem. 2003;49:1201‐4.
Google Scholar | Crossref | Medline35. Stocker, R, Yamamoto, Y, McDonagh, AF, Glazer, AN, Ames, BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043‐6.
Google Scholar | Crossref | Medline | ISI36. Seppen, J, Bosma, P. Bilirubin, the gold within. Circulation. 2012;126:2547‐9.
Google Scholar | Crossref | Medline37. Franchini, M, Targher, G, Lippi, G. Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons? Adv Clin Chem. 2010;50:47‐63.
Google Scholar | Crossref | Medline | ISI38. Levinson, SS . Relationship between bilirubin, apolipoprotein B, and coronary artery disease. Ann Clin Lab Sci. 1997;27:185‐92.
Google Scholar | Medline | ISI39. Walden, CE, Knopp, RH, Johnson, JL, Heiss, G, Wahl, PW, Hoover, JJ. Effect of estrogen/progestin potency on clinical chemistry measures. The lipid research clinics program prevalence study. Am J Epidemiol. 1986;123:517‐31.
Google Scholar | Crossref | Medline | ISI40. Luquita, MG, Catania, VA, Pozzi, EJ, et al. Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. J Pharmacol Exp Therapeut. 2001;298:49‐56.
Google Scholar | Medline41. Freeman, R . Hormone replacement therapy (estrogen and progesterone): is it necessary for heart disease prevention? Prev Cardiol. 2000;3:21‐4.
Google Scholar | Crossref | Medline42. Yamaguchi, T, Horio, F, Hashizume, T, et al. Bilirubin is oxidized in rats treated with endotoxin and acts as a physiological antioxidant synergistically with ascorbic acid in vivo. Biochem Biophys Res Commun. 1995;214:11‐9.
Google Scholar | Crossref | Medline43. Yamaguchi, T, Shioji, I, Sugimoto, A, Komoda, Y, Nakajima, H. Chemical structure of a new family of bile pigments from human urine. J Biochem. 1994;116:298‐303.
Google Scholar | Crossref | Medline44. Stender, S, Frikke-Schmidt, R, Nordestgaard, BG, Grande, P, Tybjaerg-Hansen, A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med. 2013;273:59‐68.
Google Scholar | Crossref | Medline45. Bosma, PJ, van der Meer, IM, Bakker, CT, Hofman, A, Paul-Abrahamse, M, Witteman, JC. UGT1A1*28 allele and coronary heart disease: the Rotterdam Study. Clin Chem. 2003;49:1180‐1.
Google Scholar | Crossref | Medline